DD106643A1 - - Google Patents

Info

Publication number
DD106643A1
DD106643A1 DD17394873A DD17394873A DD106643A1 DD 106643 A1 DD106643 A1 DD 106643A1 DD 17394873 A DD17394873 A DD 17394873A DD 17394873 A DD17394873 A DD 17394873A DD 106643 A1 DD106643 A1 DD 106643A1
Authority
DD
German Democratic Republic
Application number
DD17394873A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to DD17394873A priority Critical patent/DD106643A1/xx
Publication of DD106643A1 publication Critical patent/DD106643A1/xx

Links

DD17394873A 1973-07-12 1973-07-12 DD106643A1 (enrdf_load_html_response)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DD17394873A DD106643A1 (enrdf_load_html_response) 1973-07-12 1973-07-12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DD17394873A DD106643A1 (enrdf_load_html_response) 1973-07-12 1973-07-12

Publications (1)

Publication Number Publication Date
DD106643A1 true DD106643A1 (enrdf_load_html_response) 1974-06-20

Family

ID=5493031

Family Applications (1)

Application Number Title Priority Date Filing Date
DD17394873A DD106643A1 (enrdf_load_html_response) 1973-07-12 1973-07-12

Country Status (1)

Country Link
DD (1) DD106643A1 (enrdf_load_html_response)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537608A3 (en) * 1991-10-11 1993-06-16 Apogepha Arzneimittel Gmbh Process for the technical preparation of 2,2-diphenyl-2-(2-ethylbutoxy)acetic acid, 2-dimethylamino-ethyl ester
WO2009120277A1 (en) 2008-03-27 2009-10-01 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2011114195A1 (en) 2010-03-15 2011-09-22 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
WO2014025569A1 (en) 2012-08-09 2014-02-13 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
WO2017026950A1 (en) 2015-08-07 2017-02-16 Santa Farma Ilac San. A. S. Controlled release propiverine formulations
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
WO2022115056A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Sustained release formulation compositions comprising propiverine
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537608A3 (en) * 1991-10-11 1993-06-16 Apogepha Arzneimittel Gmbh Process for the technical preparation of 2,2-diphenyl-2-(2-ethylbutoxy)acetic acid, 2-dimethylamino-ethyl ester
WO2009120277A1 (en) 2008-03-27 2009-10-01 Chase Pharmaceuticals Corporation Use and composition for treating dementia
EP3178477A1 (en) 2008-03-27 2017-06-14 Chase Pharmaceuticals Corporation Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia
EP4088717A1 (en) 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2011114195A1 (en) 2010-03-15 2011-09-22 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
WO2014025569A1 (en) 2012-08-09 2014-02-13 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
CN104603108A (zh) * 2012-08-09 2015-05-06 才思制药公司 哌啶鎓季盐
US9896416B2 (en) * 2012-08-09 2018-02-20 Chase Parmaceuticals Corporation Piperidinium quaternary salts
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
WO2017026950A1 (en) 2015-08-07 2017-02-16 Santa Farma Ilac San. A. S. Controlled release propiverine formulations
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
WO2022115056A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Sustained release formulation compositions comprising propiverine

Similar Documents

Publication Publication Date Title
AR201758A1 (enrdf_load_html_response)
AU476761B2 (enrdf_load_html_response)
AU465372B2 (enrdf_load_html_response)
AR201235Q (enrdf_load_html_response)
AR201231Q (enrdf_load_html_response)
AU474593B2 (enrdf_load_html_response)
AU474511B2 (enrdf_load_html_response)
AU474838B2 (enrdf_load_html_response)
AU465453B2 (enrdf_load_html_response)
AU471343B2 (enrdf_load_html_response)
AU465434B2 (enrdf_load_html_response)
AU450229B2 (enrdf_load_html_response)
AU476714B2 (enrdf_load_html_response)
AR201229Q (enrdf_load_html_response)
AU472848B2 (enrdf_load_html_response)
AU466283B2 (enrdf_load_html_response)
AU476696B2 (enrdf_load_html_response)
AR199451A1 (enrdf_load_html_response)
AU477823B2 (enrdf_load_html_response)
AR201432A1 (enrdf_load_html_response)
AU471461B2 (enrdf_load_html_response)
AU447540B2 (enrdf_load_html_response)
AR196382A1 (enrdf_load_html_response)
AR210729A1 (enrdf_load_html_response)
AU477824B2 (enrdf_load_html_response)